INBRX 130
Alternative Names: INBRX-130Latest Information Update: 06 Jun 2024
At a glance
- Originator Inhibrx
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action CD3 antigen inhibitors; T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 30 May 2024 Inhibrx Biosciences acquires INBRX 130 from Inhibrx prior to May 2024
- 08 Apr 2022 Pharmacokinetics, pharmacodynamics and adverse events data of a preclinical trial in Solid tumours presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
- 01 Jan 2022 Preclinical trials in Solid tumours in USA (Parenteral)